

29 Aug 2021 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Pfizer buys into hematology; changes at the top at J&J; the outlook for solid tumor drug approvals; mRNA vaccine progress in India; and a look at diversity in clinical trials.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 27 August 2021, including: [Pfizer Inc.](#) buys into hematology; changes at the top at [Johnson & Johnson](#); the outlook for solid tumor drug approvals; mRNA vaccine progress in India; and a look at diversity in clinical trials.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Pfizer To Buy Trillium For \\$2.26bn In A Hematology Pipeline Play](#)" - Scrip, 23 Aug, 2021.)

(Also see "[J&J CEO Gorsky Handing Over The Reins To Vice Chairman Duato](#)" - Scrip, 20 Aug, 2021.)

(Also see "[Eight Oncology Drug Launches Expected In 2022 – Solid Tumors](#)" - Scrip, 25 Aug, 2021.)

(Also see "[Indian Biotech In mRNA Push As COVID-19 Vaccine Moves To Phase II](#)" - Scrip, 26 Aug, 2021.)

(Also see "[Breast Cancer Trial Enrollment Illustrates Diversity Challenge](#)" - Scrip, 19 Aug, 2021.)

[Click here to explore this interactive content online](#) 